Dr. Erika Spaeth

Dr. Spaeth joined the company in 2016 and is responsible for the development of clinical content and clinical rationale for GTG products. With a focus on transposing GTG’s cutting-edge approach to disease risk modeling into effortless yet actionable genetic-integrated information for both clinicians and patients, she is a cross-functional team member. She is involved in developing and executing commercial clinical research, pilot studies and managing academic research collaborations. She has wide experience in the high complexity laboratory space from assay development to regulatory oversight of laboratory developed tests in the oncology, infectious disease and inherited disease space. Her postdoctoral training was completed at MD Anderson Cancer Center where she focused on the role of the microenvironment in tumor progression. Erika holds a Ph.D. in Biomedical Sciences from the University of Texas Health Science Center and a B.S. in Molecular Biology from the University of Connecticut.